At Sapient, we believe that drugs can be developed much faster, cheaper, and more effectively through biomarker-driven drug discovery. Biomarkers allow us to better align the right patient with the right disease biology and ultimately the right therapy – and this alignment is what allows for more efficient and successful development.
That is why we have developed a transformative, three-pronged platform to enable biomarker identification with unprecedented speed and at population scale – and then make them actionable to optimize drug pipelines and advance clinical development.
Using our transformative, three-pronged platform – starting with untargeted mass spectrometry discovery screenings – we identify small molecule biomarkers with unprecedented speed and at an entirely new scale.
Download the fact sheet to learn everything that comprises the platform’s integrated pillars, including our longitudinal Human Biology Database of data from >100,000 human biosamples, rLC-MS systems for nontargeted mass spectrometry profiling of small molecule biomarkers, and expert bioinformatics team that provides the insights to rapidly discover and validate biomarkers to answer key drug development questions.
At Sapient, we believe that drugs can be developed much faster, cheaper, and more effectively through biomarker-driven drug discovery. Biomarkers allow us to better align the right patient with the right disease biology and ultimately the right therapy – and this alignment is what allows for more efficient and successful… Read More
Greater discovery is enabled when data from individual disease and cohort studies can be homogenized and linked together, revealing biological commonalities and differences across diverse populations and diseases. Sapient has built an expansive Human Biology Database for this purpose, comprised of data from hundreds of thousand of biosamples from individuals… Read More
There are tens of thousands of unmapped molecules circulating in human blood – thousands of which could represent robust biomarkers. Technologies to date have simply been too slow to map them efficiently. Sapient’s nontargeted metabolomics lab and methods – powered by next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) and a robust… Read More
Did you know that underlying risks for most common human diseases are not encoded in DNA sequence? Rather, they are revealed in circulating chemistry stemming from human exposures including diet, toxicants, internal organs, medications, and the environment. Learn how Sapient’s transformative platform can be used for untargeted biomarker discovery and… Read More
The composition and function of the human gut microbiome are linked to health and disease. Increasing evidence of gut microbes’ involvement in disease development has driven efforts to better understand the molecular mechanisms of pathogenesis from gut microbiota perturbation, to identify novel targets for therapeutic development. This requires comprehensive profiling… Read More